НОРВЕЖСКАЯ ЧЕСОТКА У БОЛЬНОГО ОСТРЫМ ЛИМФОБЛАСТНЫМ ЛЕЙКОЗОМ

A case of Norwegian scabies is described in a patient of 19 years with a lesion of the scalp, face, trunk, upper and lower extremities that occurred against the background of acute lymphoblastic leukemia. A good effect was obtained from conducting etiotropic, pathogenetic and symptomatic therapy in combination with specific treatment of the underlying disease.Описан случай норвежской чесотки у пациента 19 лет с поражением волосистой части головы, лица, туловища, верхних и нижних конечностей, протекавшей на фоне острого лимфобластного лейкоза. Получен хороший эффект от проведения этиотропной, патогенетической и симптоматической терапии в комплексе со специфическим лечением основного заболевания

Modern means for the treatment of inflammatory diseases of periodont: Used forms, perspectives of improvement with the use of the components of mineral origin

The review presents modern methods of therapeutic treatment of periodontal disease using a variety of drugs. The advantages and disadvantages of the use of drugs in various dosage forms and medical devices are presented. The actual direction in development of new means of hygiene and care of the oral cavity based on the use of natural mineral salts for non-drug therapy of periodontal diseases is revealed. © 2018 Stavropol State Medical University. All Rights Reserved

The oldest volcanic glass in the early paleoproterozoic boninite-type lavas, Karelian craton: Results of instrumental investigations

Since Early Precambrian volcanic rocks are typically strongly altered by superimposed processes, they retain primary composition and texture only in exceptional cases. Such a case is observed in the Early Paleoproterozoic volcanic rocks of the Vetrenyi Belt Formation of the synonymous riftogenic structure in southeastern Karelia, where volcanic glass is locally preserved [1-3]. The Sm-Nd, Re-Os, and U-Pb (zircon) ages of volcanic rocks of this formation range from 2.5 Ga in the lower parts to 2.41 Ga in the upper parts of the sequence [1-3]. Zolotykh and Ladygin [4, 5] also confirmed the presence of volcanic glass in these rocks. During short-term field works in 2000, we collected additional samples in the southeastern termination of the graben-shaped Vetrenyi Belt, where the least altered rocks were preserved. The samples were mainly treated at the Institute of Geology of Ore Deposits, Petrography, Mineralogy, and Geochemistry

The oldest volcanic glass in the early paleoproterozoic boninite-type lavas, Karelian craton: Results of instrumental investigations

Since Early Precambrian volcanic rocks are typically strongly altered by superimposed processes, they retain primary composition and texture only in exceptional cases. Such a case is observed in the Early Paleoproterozoic volcanic rocks of the Vetrenyi Belt Formation of the synonymous riftogenic structure in southeastern Karelia, where volcanic glass is locally preserved [1-3]. The Sm-Nd, Re-Os, and U-Pb (zircon) ages of volcanic rocks of this formation range from 2.5 Ga in the lower parts to 2.41 Ga in the upper parts of the sequence [1-3]. Zolotykh and Ladygin [4, 5] also confirmed the presence of volcanic glass in these rocks. During short-term field works in 2000, we collected additional samples in the southeastern termination of the graben-shaped Vetrenyi Belt, where the least altered rocks were preserved. The samples were mainly treated at the Institute of Geology of Ore Deposits, Petrography, Mineralogy, and Geochemistry

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007. © 2020 Hellenic Society of Cardiolog

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and 651 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and 64 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores 642. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007